Sponsor:
Regeneron Pharmaceuticals
Code:
NCT07675824
Conditions
Primary Open Angle Glaucoma (POAG)
Ocular Hypertension (OHT)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
REGN22530
Brief summary:
Conditions
Primary Open Angle Glaucoma (POAG)
Ocular Hypertension (OHT)
Study ID
NCT07675824
Start date
Sep 8, 2026
Status verified date
Sep, 2026
Completion date
Dec 6, 2029
Anticipated
Primary completion date
Sep 14, 2029
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
271 participants
Anticipated
Allocation
Randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
experimental: Phase 1 Part A
experimental: Phase 1 Part B
experimental: Phase 2 Part C
Interventions
REGN22530
Primary outcome measure
Central contacts
Locations
Advanced Research
Recruiting
Deerfield Beach, Florida, United States, 33064
Sponsor
Regeneron Pharmaceuticals
Last update posted
Sep 28, 2026
Last verified
Sep, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-29. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-09-28. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.